Recorded fact · drug.label_indication
drug.label_indication for lenalidomide|mantle-cell-lymphoma
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 298d954b resolves to.
The record
| Fact id | 298d954b4c1d9b44e2545170 |
|---|---|
| Entity | drug: lenalidomide|mantle-cell-lymphoma |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20230324 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 028e4b3914662e5aaf0a28bf360239eb0b65b6135211411f789a679e07c6ef54.
The value
{
"ingredient": "Lenalidomide",
"conditionId": "mantle-cell-lymphoma",
"conditionName": "Mantle Cell Lymphoma",
"matchedAlias": "Mantle cell lymphoma",
"context": "indication",
"brand": "Revlimid",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "5fa97bf5-28a2-48f1-8955-f56012d296be",
"labelEffectiveTime": "20230324",
"labelsRead": 14,
"labelsNaming": 10,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 3cb349aefe5de9a20a04a1f2733fea4c01d82e2d5a8f16f46b1d5518050c49cc.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.